Near to Infrared (NIR) Light Neuroprotection in Glaucomatous Optic Neuropathy

Early Phase 1UnknownNCT00844389

Universidad de Valparaiso40 enrolled

Overview

The purpose of the study is to evaluate if near-to-infrared light stimulation can improve retinal ganglion cell function in glaucomatous patients.

Ganglion cell dysfunction in glaucomatous optic neuropathy has been ascribed to ganglion cell electrophysiological inactivation and to apoptotic cell death. Near-to-infrared light stimulation has been used to induce mitochondrial activation and to prevent apoptotic death through mitochondrial cytochrome oxidase c stimulation. Near-to-infrared light stimulation might be useful to induce ganglion cell activation and inhibit apoptotic cell death. We propose that near-to-infrared light stimulation can be used as an adjuvant treatment combined with ocular hypotensive treatment in glaucomatous patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Open Angle Glaucoma

Interventions

Near to infrared light retinal stimulationDEVICE

Patients will be stimulated with 660 nm light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.

Green light stimulationDEVICE

Patients will be stimulated with 530 nm LED light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnose of Ocular Hypertension (cup to disk ratio 0,6 or less, normal Humphrey 24-2 visual field with aplanatic IOP over 21 mmHg) or Mild Glaucoma (cup to disk ratio 0,6 to 0,8, characteristic Humphrey 24-2 visual field defect PSD between 3 and 6 dB). * Visual acuity 20/40 or better Exclusion Criteria: * Diabetic retinopathy, Multiple Sclerosis, Parkinson disease * Refractive error of 3 diopters or more

Locations (1)

Servicio de Oftalmología Hospital Van Buren

Valparaíso, Región de Valparaíso, Chile

Outcomes

Primary Outcomes

Pattern electroretinogram response

Time frame: Every two weeks for 4 months

Secondary Outcomes

OCT ganglion cell layer average thickness, Visual Field defects

Time frame: Every month for four months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.